



## **PRESS RELEASE**

**innate pharma®**

---

### **INNATE PHARMA STRENGTHENS ITS MANAGEMENT TEAM**

**Stéphane Boissel, ex-Lazard and PwC, is named Chief Financial Officer with responsibility for corporate and business development.**

**Marseilles, February 28th, 2003**

---

Innate Pharma, developer of novel anti-tumoral therapies, announces today the appointment of Stéphane Boissel, 35, as Chief Financial Officer. Boissel's responsibilities will also cover Corporate Development (mergers and acquisitions) and Business Development (in-licensing and out-licensing).

Prior to joining Innate Pharma, Stéphane Boissel spent more than seven years with Groupe Lazard, in its French and international offices (Singapore and Hong Kong). He started up the technology investment activities of Eurazeo, a member of the Lazard group, in 1995. He was in charge of Lazard's technology fund in Asia before joining the group's Asian M&A department as head of technology activities till January 2002. Back in France, he was director of investments at Eurazeo until August 2002. Before joining Lazard, Stéphane Boissel spent four years as auditor and consultant in PwC in Paris.

Boissel has an MBA from the University of Chicago. He has a number of French university and professional qualifications including an MSG and DEA from Lyon and Paris-Dauphine and DESCF (accounting) and SFAF (financial analyst).

*"The appointment of Stéphane Boissel is a further step in Innate's development coming as it does after the highly successful fund raising last year," said Hervé Brailly, CEO of Innate Pharma. "His international experience and skills in various financial roles mean we can confidently meet the challenges involved in the next stages of Innate's development."*

---